Global Drug Eluting Stents Market Industry Trends, Share, Size, Growth, Opportunity, and Forecasts
A stent is a small mesh tube that is placed inside an artery to keep it open. A slow-release medication is coated on a drug-eluting stent. Clotting in a stent can lead to restenosis and a heart attack in the future. A bare-metal stent is one that does not have a drug coating.
The global drug eluting stents market is divided into four segments: coating, application, end user, and region. The market is divided into two types of coating: polymer-based coating and polymer-free coating. Polymer-based coatings are further classified as biodegradable and non-biodegradable. The segment of polymer-free coating is further subdivided into microporous surface, microstructure surface, slotted tubular surface, and nonporous surface. The market is divided into two applications: coronary artery disease and peripheral artery disease. Based on end-user, the market is divided into hospitals, ambulatory surgical centres, and others. North America, Europe, Asia-Pacific, and Latin America and the Caribbean make up the market's four regions.
The global Drug Eluting Stents Market is estimated to be valued at US$ 2,410.8 million in 2019, and is expected to witness a CAGR of 6.4% during the forecast period (2019–2027).
Because of favourable reimbursement policies and a high incidence rate of artery diseases in this region, North America is expected to hold a significant market share in the drug eluting stent market. According to the Centres for Disease Control and Prevention (CDC), coronary heart disease claimed the lives of Twenty thousand people in the United States. Furthermore, approximately two out of every ten deaths from coronary artery disease occur in adults under the age of sixty-five. Furthermore, technological advancements in drug-eluting stents and the presence of well-established healthcare infrastructure are fuelling the overall regional market's growth to a large extent. Currently, the polymer-free coating segment is the largest revenue contributor and is expected to grow significantly during the forecast period. Lower in-stent restenosis rates, faster drug-eluting rates, and higher drug loading capacity of nonporous surfaces all contribute to DES's widespread use. Furthermore, the polymer-free coating has advantages such as avoiding inflammatory issues caused by polymers used in stents by excluding polymer coating entirely and releasing anti-proliferative drugs directly from the stent surface.

Comments
Post a Comment